ANTI-VIRUS AGENT AND METHOD FOR TREATMENT OF VIRAL INFECTION
A method of treatment of viral infection in a subject comprising administering to the subject a copolymer comprising an acrolein derived segment or a polyacrolein oligomer segment and a polyalkylene glycol oligomer segment, the copolymer having a molecular weight of no more than 1500 Daltons.
1 .- 30 . (canceled)
31 . A method of treatment of a parenteral viral infection in a subject comprising administering to the subject a copolymer comprising an acrolein-derived segment and a polyalkylene glycol oligomer segment, the copolymer having a molecular weight of no more than 1000 Daltons.
32 . The method according to claim 31 , wherein the acrolein-derived segment is a polyacrolein oligomer comprising two or more acrolein residues.
33 . The method according to claim 31 , wherein the copolymer has a molecular weight of from 300 to 1000 Daltons.
34 . The method according to claim 31 , wherein the polyalkylene glycol oligomer segment has a molecular weight in the range of from 200 to 600 Daltons.
35 . The method according to claim 31 , wherein the polyalkylene glycol oligomer segment has a molecular weight in the range of from 200 to 400 Daltons.
36 . The method according to claim 31 , wherein a polyalkylene glycol of the polyalkylene glycol oligomer segment is polyethylene glycol.
37 . The method according to claim 31 , wherein the copolymer has a molecular weight of from 400 to 800 Daltons.
38 . The method according to claim 31 , wherein the copolymer is administered systemically.
39 . The method according to claim 31 , wherein the copolymer is administered by a route selected from the group consisting of oral administration, inhalation, transdermal delivery and injection.
40 . The method according to claim 31 , wherein the copolymer is administered by oral administration.
41 . The method according to claim 31 , wherein the copolymer is administered by intravenous injection or infusion.
42 . The method according to claim 31 , wherein the copolymer is administered as an aqueous solution comprising a copolymer concentration in the range of from 0.01% by weight to 20% by weight of the aqueous solution.
43 . The method according to claim 31 , wherein the copolymer is administered orally in the form of a tablet, caplet, syrup or liquid.
44 . The method according to claim 31 , wherein the copolymer is administered systemically at a dose in the range of from 1 mg to 1000 mg per kilogram of bodyweight per day.
45 . The method according to claim 31 , wherein the parenteral viral infection is selected from the group consisting of a influenza viral infection, an HIV infection, a hepatitis viral infection, a Ross River viral infection, and a herpes viral infection.
46 . The method according to claim 31 , wherein the parenteral viral infection is an influenza viral infection.
47 . A process of preparing a copolymer comprising an acrolein-derived segment and a polyalkylene glycol oligomer comprising:
adding a first aqueous solution comprising an acrolein having an acrolein concentration of no more than 50% w/w by weight of the first aqueous solution to a second aqueous solution comprising polyethylene glycol and at least 10% w/w water by weight of the second aqueous solution; thereby forming a third aqueous solution; and
polymerizing the acrolein under conditions of alkaline catalysis at a pH no more than 12 in the third aqueous solution, and thereby forming a copolymer, wherein:
the molecular weight of the polyalkylene glycol is from 200 to 600 Daltons and the copolymer has a molecular weight of no more than 1000 Daltons;
the second aqueous solution has a pH of no more than 12.0;
the third aqueous solution comprises at least 20% w/w water by weight of the third aqueous solution; and
the copolymer has a weight ratio of polyalkylene glycol:acrolein of at least 4:1.
48 . The process according to claim 47 , wherein the second aqueous solution has a pH of from 9 to 11.
49 . The process according to claim 47 , wherein:
the second aqueous solution is a mildly basic aqueous solution having a pH of no more than 12.0;
the polyalkylene glycol has a molecular weight in the range of from 200 to 600 Daltons;
the mildly basic solution is stirred vigorously to entrain air;
the first aqueous solution is added over a period of at least 2 minutes the polymerization temperature is maintained in the range of from 10° C. to 40° C.; and
acid is added to provide a pH less than 9 once the acrolein has been consumed.
50 . A copolymer effective in treatment of parenteral viral infection in a subject by systemic administration, the copolymer comprising an acrolein-derived segment and a polyalkylene glycol oligomer segment wherein:
the copolymer has a molecular weight of no more than 1000 Daltons; and
the polyalkylene glycol oligomer segment has a molecular weight in the range of 200 to 600 Daltons.